N'-[3-(2,4-dichloro-6-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N-(oxan-4-yl)ethane-1,2-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N'-[3-(2,4-dichloro-6-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N-(oxan-4-yl)ethane-1,2-diamine
• 化学式: C₂₂H₂₇Cl₂N₅O₂
• 分子量: 464.4
• InChiKey: NYBQWAQWSSOYLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  72.7
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Piperazine derivatives and process for the preparation thereof
  申请人：Samjin Pharmaceutical Co., Ltd.

  公开号：US20030092910A1

  公开（公告）日：2003-05-15

  The present invention relates to a novel compound of the general formula (I) and its pharmaceutically acceptable acid addition salt, and process for the preparation thereof, which have strong antimumor activities and very low toxicity. 1 wherein R 1 and R 2 are independently hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkylcarboxyl, C 1 -C 4 alkylcarbonyl, C 1 -C 4 alkoxy, C 1 -C 4 hydroxyalkyl, C 1 -C 4 aminoalkyl or C 1 -C 4 hydroxyiminoalkyl, or R 1 and R 2 are fused to form C 3 -C 4 unsaturated ring; R 3 , R 4 , R 5 , R 6 and R 7 are independently hydrogen, halogen, hydroxy, nitro, amino, C 1 -C 4 alkyl, C 1 -C 4 alkylcarboxyl, C 1 -C 4 alkylcarbonyl, C 1 -C 4 alkoxy or C 1 -C 4 thioalkoxy; R 8 is C 1 -C 4 alkyl; Y is oxygen, sulphur, amino, substituted amino or C 1 -C 4 thioalkyl; Z is C 1 -C 4 alkoxy, C 1 -C 4 alkyl C 1 -C 4 alkylamino or C 1 -C 4 thioalkoxy; X 1 and X 2 are independently carbon or nitrogen; and —N═C— and —C═Y— may form a single bond or a double bond provided that if —N═C— forms a single bond, —C═Y— forms a double bond, and if —C═Y— forms a single bond, —N═C— forms a double bond and R 8 is nonexistent.

  本发明涉及一种新型化合物，其通式为(I)，及其药学上可接受的酸盐，并涉及其制备方法，该化合物具有很强的抗肿瘤活性和极低的毒性。其中R1和R2独立地为氢、C1-C4烷基、C1-C4烷基羧基、C1-C4烷基羰基、C1-C4烷氧基、C1-C4羟基烷基、C1-C4氨基烷基或C1-C4羟基亚烷基，或者R1和R2融合形成C3-C4不饱和环；R3、R4、R5、R6和R7独立地为氢、卤素、羟基、硝基、氨基、C1-C4烷基、C1-C4烷基羧基、C1-C4烷基羰基、C1-C4烷氧基或C1-C4硫氧基；R8为C1-C4烷基；Y为氧、硫、氨基、取代氨基或C1-C4硫代烷基；Z为C1-C4烷氧基、C1-C4烷基、C1-C4烷基氨基或C1-C4硫代烷氧基；X1和X2独立地为碳或氮；且-N═C—和—C═Y—可以形成单键或双键，条件是如果—N═C—形成单键，则—C═Y—形成双键，如果—C═Y—形成单键，则—N═C—形成双键，且R8不存在。
• Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines
  申请人：Neurogen Corporation

  公开号：US20030069246A1

  公开（公告）日：2003-04-10

  Disclosed are compounds of the formula: 1 where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and X are defined herein. These compounds are selective modulators of NPY1 receptors. These compounds are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of NPY1 receptors and as standards in assays for NPY1 receptor binding. Methods of using the compounds in receptor localization studies are given.

  本发明揭示了以下化合物的公式：1其中R1、R2、R3、R4、R5、R6和X在此定义。这些化合物是NPY1受体的选择性调节剂。这些化合物在治疗许多中枢神经系统疾病、代谢性疾病和外周疾病，特别是进食障碍和高血压方面非常有用。本发明还提供了治疗这些疾病的方法以及包装的制药组合物。本发明的化合物还可用作NPY1受体定位的探针，以及在NPY1受体结合测定中的标准。给出了在受体定位研究中使用这些化合物的方法。
• CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES
  申请人：NEUROGEN CORPORATION

  公开号：EP1218379A2

  公开（公告）日：2002-07-03
• US6372743B1
  申请人：——

  公开号：US6372743B1

  公开（公告）日：2002-04-16
• [EN] CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES<br/>[FR] PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES A SUBSTITUTION ALKYLENE-DIAMINE ET PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
  申请人：NEUROGEN CORP

  公开号：WO2001023387A2

  公开（公告）日：2001-04-05

  Disclosed are compounds of formula (I), where R?1, R2, R3, R4, R5, R6¿, and X are defined herein. These compounds are selective modulators of NPY1 receptors. These compounds are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of NPY1 receptors and as standards in assays for NPY1 receptor binding. Methods of using the compounds in receptor localization studies are given.